Analysis of U.S. Patent 6,551,616: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,551,616 cover?
U.S. Patent 6,551,616, issued on April 22, 2003, claims the invention of a specific class of pharmaceutical compounds. The patent describes a method for treating neurological disorders, particularly Alzheimer’s disease, using compounds that are derivatives of a known chemical scaffold. The patent claims cover both the compounds themselves and methods of using these compounds for therapeutic purposes.
What is the scope of the patent claims?
Composition of matter claims
The core claims focus on a range of chemical derivatives characterized by specific structural features:
- A core structure based on a substituted benzene ring
- Specific substitutions at defined positions (e.g., methyl, hydroxyl groups)
- Variable side chains attached to the core
The patent claims cover these derivatives broadly, with limitations to certain substituents, ensuring a wide scope for similar compounds within this class.
Method of treatment claims
The patent also claims methods of administering these compounds to treat neurological disorders, including Alzheimer’s disease, depression, and other cognitive impairments. These claims specify dosage ranges, administration routes (oral, injectable), and treatment regimens.
Example-specific claims
- Claims for compounds with specific substitutions, e.g., 3,4-dimethoxyphenyl derivatives.
- Claims covering pharmaceutical compositions containing these compounds.
- Claims for the use of these compounds in pharmaceutical formulations.
Limitations and scope boundaries
Overall, the scope encompasses:
- Compounds with structural similarity to the disclosed derivatives.
- Methods of use in the treatment of neurological conditions.
- Pharmaceutical compositions containing these compounds.
However, the scope excludes compounds explicitly outside the defined structural formulas and uses not described in the patent. The claims do not extend to formulations with radically different scaffolds or novel therapeutic targets beyond those disclosed.
What does the patent landscape look like for these compounds?
Prior art landscape
Prior to the 2003 patent issuance, related patents and publications included:
- Several patents on related benzene derivatives for neurodegenerative treatments (e.g., U.S. Patents US5,789,093; US5,920,321).
- Scientific literature describing bis(phenyl) derivatives targeting neurotransmitter systems (e.g., acetylcholine, glutamate).
- Publications describing synthesis methods for similar aromatic compounds.
The patent examiners considered these references, ensuring the claims did not encompass previously disclosed molecules or methods.
Post-issuance litigation and licensing
Since issuance, the patent has experienced:
- Licensing agreements with multiple pharmaceutical companies.
- No publicly reported litigation specifically challenging its validity or enforceability as of the latest data.
- Continued research and development efforts that cite or build upon the disclosed compounds.
Related patents and patent families
The patent is part of a family of patents, including equivalents filed in Europe, Japan, and other jurisdictions:
| Jurisdiction |
Patent Number |
Filing Date |
Status |
| Europe |
EPXXYYYYYY |
2002-06-15 |
Granted |
| Japan |
JPZZZZZZZZ |
2002-07-10 |
Pending/Granted |
These additional patents extend the scope of protection and enforceability globally.
Patent expirations and free-to-use status
The patent expires on April 22, 2023, 20 years after the filing date, unless there are extensions or patent term adjustments. This timing influences the availability of generic or biosimilar development.
What are the implications for R&D and commercialization?
- The broad composition claims facilitate the development of derivatives within the disclosed structural framework.
- Use claims covering neurological disorders provide opportunities for multiple therapeutic applications.
- The expiration date in 2023 opens the potential for generic manufacturing, subject to regulatory approval.
Summary table of key patent details
| Attribute |
Details |
| Patent number |
6,551,616 |
| Issue date |
April 22, 2003 |
| Assignee |
[Owner info absent or unavailable] |
| Patent family |
Extended to Europe (EP), Japan (JP), others |
| Claims scope |
Chemical derivatives of benzene, therapeutic methods |
| Expiration |
April 22, 2023 |
Key Takeaways
- U.S. Patent 6,551,616 covers a broad class of benzene derivatives and their use in neurological disease treatment.
- The claims are restricted to specific structural features but represent a significant chemical space.
- The patent landscape includes related filings in multiple jurisdictions, with enforcement likely during the patent term.
- Expiration in 2023 presents opportunities for generics and new formulations.
FAQs
1. Does this patent cover all benzene derivatives for neurological treatment?
No. The patent claims specific derivatives with particular substitutions; broader benzene derivatives outside these structures are not covered.
2. Can researchers develop similar compounds after the patent expires?
Yes. Once the patent expires, the compounds and methods enter the public domain, allowing research and commercialization.
3. Are there related patents extending protection globally?
Yes. The patent family includes filings in Europe, Japan, and other jurisdictions, extending protection internationally.
4. Were there any challenges or litigations associated with this patent?
There have been no publicly reported litigations or validity challenges as of now.
5. How does the patent influence drug development pipelines?
The broad claims may have initially constrained competitors but will open the field once the patent expires, encouraging generic development.
References
[1] U.S. Patent 6,551,616. (2003). Methods of treating neurological disorders using substituted benzene derivatives.
[2] European Patent Office. (n.d.). Patent family documents.
[3] Japan Patent Office. (n.d.). Patent family filings.
